Tagged with Public private

Pharma Following regulatory changes, CSL Behring is now able to offer plasma fractionation and purification services to Italy’s public healthcare sector for the first time. General manager Oliver Schmitt discusses the added value and savings CSL Behring can offer in this service segment and the benefits its newest generation of innovative…

Pharma Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the impact of medtech innovations. What are the exact activities of Assobiomedica and what are your main priorities as President? The…

Pharma The AIFP’s Jakub Dvořáček explains the recently launched tool for information disclosure between pharmaceutical companies and doctors, highlighting the significance it holds for industry and country. Furthermore, he reviews the Czech Republic’s attractiveness as a location for pharma companies. When we met you in 2012, you named re-exporting and a…

Pharma In keeping with its reputation as a forerunner, the Dutch healthcare eco-system is currently reinventing itself to ensure it remains ahead of the game in terms of both innovation and excellence. Market and patient access, transparency, cost-effectiveness and process innovation all feature prominently as industry and government alike band together…

Pharma Takeda’s goal is to become a trusted and reliable partner in the healthcare system by better understanding patients’ needs. Aarnoud Overkamp, general manager of the Dutch subsidiary, shares his perspective on the challenges faced by the local healthcare system, the importance of Takeda-ism in the organization, and finding innovative ways…

Pharma The chairman of Egypt’s largest holding company for pharmaceutical manufacturers, ACDIMA, shares his vision for how Egyptian manufacturers can enhance their competitiveness in the coming years, and extend their activities further up the value chain into API production and R&D activities. How well prepared are Egyptian companies to compete in…

Pharma Yvonne van Rooy, president of the NVZ, explains the patient’s increasing role as a partner in Dutch healthcare and how greater investment in ICT is needed for the patient to fulfill this role. She further discusses the need for more transparency in the pharmaceutical industry and highlights the need for all stakeholders in the industry to…

Pharma Prof. Thierry Philip, President of Institut Curie, is proud of the model that the institute is thriving for: excellent science and research in all forms, from the most basic to applied clinical medicine. As a Cancer Biology Center, it is not only one of the top institutes in France, but…

Pharma Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently being implemented in the regulatory system will have on the industry moving forward.   Dr. Piliounis, to start off, you…

Pharma Prof. Manuela Battaglia (MB) and  Prof. Lorenzo Piemonti (LP) discuss the positioning of the Diabetes Research Institute (DRI) within the San Raffaele Scientific Institute and the global diabetes care community, their respective specialty areas and DRI’s commitment to translational medicine. The Diabetes Research Institute (DRI) is part of the International…

Pharma Tania Zulu Holt, Associate Principal at McKinsey & Company elaborates on the current pressures on the South African healthcare system, discusses the importance of innovation and emphasizes the need for a hybrid model between the public and private sector to meet the healthcare needs of the country’s population. Can you…

Pharma A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through complementary health insurance, and breaking with the egalitarian principle that everybody should be reimbursed to the same extent irrespective of…